News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
710,122 Results
Type
Article (44764)
Company Profile (690)
Press Release (664668)
Section
Business (212119)
Career Advice (2671)
Deals (37654)
Drug Delivery (110)
Drug Development (83357)
Employer Resources (175)
FDA (16553)
Job Trends (16172)
News (359102)
Policy (33934)
Tag
Academia (2563)
Alliances (52293)
Alzheimer's disease (1312)
Approvals (16472)
Artificial intelligence (152)
Bankruptcy (379)
Best Places to Work (12007)
Biotechnology (474)
Breast cancer (126)
Cancer (1128)
Cardiovascular disease (104)
Career advice (2225)
Cell therapy (261)
Clinical research (66144)
Collaboration (412)
Compensation (198)
COVID-19 (2652)
C-suite (104)
Data (1137)
Diabetes (157)
Diagnostics (6479)
Earnings (84790)
Employer resources (153)
Events (116712)
Executive appointments (323)
FDA (17092)
Funding (368)
Gene therapy (189)
GLP-1 (661)
Government (4414)
Healthcare (19175)
Infectious disease (2742)
Inflammatory bowel disease (115)
Interviews (502)
IPO (17247)
Job creations (4591)
Job search strategy (1871)
Layoffs (481)
Legal (8319)
Lung cancer (179)
Manufacturing (197)
Medical device (13967)
Medtech (13972)
Mergers & acquisitions (20464)
Metabolic disorders (441)
Neuroscience (1614)
NextGen Class of 2024 (7061)
Non-profit (4323)
Northern California (1507)
Obesity (254)
Opinion (237)
Patents (107)
People (59793)
Pharmaceutical (137)
Phase I (20545)
Phase II (29320)
Phase III (21991)
Pipeline (463)
Postmarket research (2354)
Preclinical (8608)
Radiopharmaceuticals (255)
Rare diseases (233)
Real estate (6527)
Regulatory (22563)
Research institute (2358)
Resumes & cover letters (420)
Southern California (1324)
Startups (4049)
United States (14240)
Vaccines (618)
Weight loss (202)
Date
Today (137)
Last 7 days (791)
Last 30 days (3909)
Last 365 days (37713)
2024 (34594)
2023 (41998)
2022 (52985)
2021 (57414)
2020 (55570)
2019 (48654)
2018 (36859)
2017 (34778)
2016 (34497)
2015 (40172)
2014 (33142)
2013 (27714)
2012 (29270)
2011 (29638)
2010 (27123)
Location
Africa (877)
Arizona (162)
Asia (43176)
Australia (7077)
California (3494)
Canada (1305)
China (254)
Colorado (153)
Connecticut (164)
Europe (94887)
Florida (461)
Georgia (121)
Illinois (367)
Indiana (213)
Kansas (99)
Maryland (589)
Massachusetts (2837)
Michigan (170)
Minnesota (291)
New Jersey (992)
New York (990)
North Carolina (827)
Northern California (1507)
Ohio (142)
Pennsylvania (855)
South America (1263)
Southern California (1324)
Texas (498)
Washington State (389)
710,122 Results for "par pharmaceutical companies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Par Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is expanding its voluntary recall to include seven lots of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level. The product is being recalled due to the potential for the presence of silicone particulates in the product.
April 22, 2024
·
5 min read
Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is voluntarily recalling one lot of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level.
March 12, 2024
·
4 min read
Domain Therapeutics to Present Latest Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology, at AACR 2024 Annual Meeting, Highlighting Clear Competitive Advantages of This Candidate
Domain Therapeutics (“Domain” or “the Company”) today announces that latest preclinical data on DT-9045, a novel protease-activated receptor 2 (PAR2) Negative Allosteric Modulator candidate, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.
March 26, 2024
·
4 min read
Lone Star Bio
CNS Pharmaceuticals to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
CNS Pharmaceuticals, Inc. today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners on May 21, 2024 at 1:40 PM ET.
May 20, 2024
·
1 min read
Press Releases
Samsung Biologics signs manufacturing deal with European pharmaceutical company
November 20, 2024
·
3 min read
Pharm Country
Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
Tonix Pharmaceuticals Holding Corp. announced today that Seth Lederman, M.D., Chief Executive Officer, will participate virtually in a fireside chat at A.G.P.’s Healthcare Company Showcase on Tuesday, May 21, 2024, at 9:00 a.m. ET.
May 15, 2024
·
3 min read
Press Releases
Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement
October 17, 2024
·
3 min read
Genetown
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
Pieris Pharmaceuticals, Inc. announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024.
April 19, 2024
·
4 min read
Press Releases
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth
October 28, 2024
·
11 min read
Deals
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
Corvus Pharmaceuticals, Inc. today announced that it has entered into a securities purchase agreement with new and existing investors to raise approximately $30.6 million dollars in aggregate gross proceeds through the sale of shares of its common stock, par value $0.0001 per share.
May 2, 2024
·
5 min read
1 of 71,013
Next